Donata Ponikwicka-Tyszko

Dr. Donata Ponikwicka-Tyszko


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2019 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
MCMarcin Chrusciel
Marcin Chrusciel
DPDonata Ponikwicka-Tyszko
Donata Ponikwicka-Tyszko
SWSlawomir Wolczynski
Slawomir Wolczynski
IHIlpo Huhtaniemi
Ilpo Huhtaniemi
Nafis RahmanNafis Rahman
Nafis Rahman
Expression of the follicle-stimulating hormone receptor (FSHR), besides gonadal tissues, has recently been detected in several extragonadal normal and tumorous tissues, including different types of primary and metastatic cancer and tumor vessel endothelial cells (TVEC). The suggested FSH actions in extragonadal tissues include promotion of angiogenesis, myometrial contractility, skeletal integrity, and adipose tissue accumulation. Non-malignant cells within cancer tissue have been shown to be devoid of FSHR expression, which implies a potential role of FSHR as a diagnostic, prognostic, or even a therapeutic tool. There are shared issues between several of the published reports questioning the validity of some of the conclusion. Firstly, protein expression of FSHR was performed solely with immunohistochemistry (IHC) using either an unavailable “in house” FSHR323 monoclonal antibody or poorly validated polyclonal antibodies, usually without additional methodological quality control and confirmations. Secondly, there is discrepancy between the hardly traceable or absent FSHR gene amplification/transcript data and non-reciprocal strong FSHR protein immunoreactivity. Thirdly, the pharmacological high doses of recombinant FSH used in in vitro studies also jeopardizes the physiological or pathophysiological meaning of the findings. We performed in this review a critical analysis of the results presenting extragonadal expression of FSHR and FSH action, and provide a rationale for the validation of the reported results using additional more accurate and sensitive supplemental methods, including in vivo models and proper positive and negative controls.

1 July 2016 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
DPDonata Ponikwicka-Tyszko
Donata Ponikwicka-Tyszko
MCMarcin Chrusciel
Marcin Chrusciel
JSJoanna Stelmaszewska
Joanna Stelmaszewska
PBPiotr Bernaczyk
Piotr Bernaczyk
MSMaria Sztachelska
Maria Sztachelska
NRNafis A. Rahman
Nafis A. Rahman
Article published by the Endocrine Society Article published by the Endocrine Society

19 September 2011 in Insect Conservation and Diversity
Verified
Journal Article
Closed access
PDF file
MSMarcin Sielezniew
Marcin Sielezniew
RRRobert Rutkowski
Robert Rutkowski
DPDonata Ponikwicka-Tyszko
Donata Ponikwicka-Tyszko
MRMirosław Ratkiewicz
Mirosław Ratkiewicz
IDIzabela Dziekańska
Izabela Dziekańska
GŠGiedrius Švitra
Giedrius Švitra

1 September 2019 in EBioMedicine
Verified
Journal Article
Open access
DPDonata Ponikwicka-Tyszko
Donata Ponikwicka-Tyszko
MCMarcin Chrusciel
Marcin Chrusciel
JSJoanna Stelmaszewska
Joanna Stelmaszewska
PBPiotr Bernaczyk
Piotr Bernaczyk
PCPaulina Chrusciel
Paulina Chrusciel
Nafis RahmanNafis Rahman
Nafis Rahman
Recent clinical trials on ovarian cancer with mifepristone (MF) have failed, despite in vitro findings on its strong progesterone (P4) antagonist function. Ovarian cancer human and murine cell lines, cultured high-grade human primary epithelial ovarian cancer (HG-hOEC) cells and their explants; as well as in vivo transgenic mice possessing ovarian cancer were used to assess the molecular mechanism underlying mifepristone (MF) agonistic actions in ovarian cancer progression. Herein, we show that ovarian cancer cells express traceable/no nuclear P4 receptor (PGR), but abundantly P4 receptor membrane component 1 (PGRMC1). MF significantly stimulated ovarian cancer cell migration, proliferation and growth in vivo, and the translocation of PGRMC1 into the nucleus of cancer cells; the effects inhibited by PGRMC1 inhibitor. The beneficial antitumor effect of high-doses MF could not be achieved in human cancer tissue, and the low tissue concentrations achieved with the therapeutic doses only promoted the growth of ovarian cancers. Our results indicate that treatment of ovarian cancer with MF and P4 may induce similar adverse agonistic effects in the absence of classical nuclear PGRs in ovarian cancer. The blockage of PGRMC1 activity may provide a novel treatment strategy for ovarian cancer. FUND: This work was supported by grants from the National Science Centre, Poland (2013/09/N/NZ5/01831 to DP-T; 2012/05/B/NZ5/01867 to MC), Academy of Finland (254366 to NAR), Moikoinen Cancer Research Foundation (to NAR) and EU PARP Cluster grant (UDA-POIG.05.01.00-005/12-00/NCREMFP to SW).

Verified
Journal Article
Open access
PDF file
MSMaria Sztachelska
Maria Sztachelska
DPDonata Ponikwicka-Tyszko
Donata Ponikwicka-Tyszko
LMLydia Martínez-Rodrigo
Lydia Martínez-Rodrigo
PBPiotr Bernaczyk
Piotr Bernaczyk
EPEwelina Palak
Ewelina Palak
SWSławomir Wołczyński
Sławomir Wołczyński
Adenomyosis is a common gynaecological disease associated with the presence of endometrial lesions in the uterine myometrium. Estrogens have been proven to be the crucial hormones driving the growth of adenomyosis. Little is known about the distinct mechanisms of progesterone action in adenomyosis. Hence, in this study, we decided to characterize the expression of all nuclear and membrane estrogen and progesterone receptors. Additionally, as a functional investigation, we monitored prolactin production and cell proliferation after estradiol and progesterone treatments. We confirmed the presence of all nuclear and membrane estrogen and progesterone receptors in adenomyotic lesions at gene and protein levels. The expression of membrane progesterone receptors α and β (mPRα, mPRβ) as well as estrogen receptor β (ERβ) was upregulated in adenomyosis compared to normal myometrium. Estradiol significantly increased adenomyotic cell proliferation. Progesterone and cAMP upregulated prolactin secretion in adenomyosis in the same pattern as in the normal endometrium. In the present study, we showed the functional link between estradiol action and adenomyotic cell proliferation, as well as progesterone and prolactin production. Our findings provide novel insights into the sex steroid receptor expression pattern and potential regulated pathways in adenomyosis, suggesting that all receptors play an important role in adenomyosis pathophysiology.

22 October 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MLMei Liu
Mei Liu
YDYaqi Du
Yaqi Du
Hai-Wen LiHai-Wen Li
Hai-Wen Li
LWLi Wang
Li Wang
DPDonata Ponikwicka-Tyszko
Donata Ponikwicka-Tyszko
XLXiangdong Li
Xiangdong Li
Expression patterns of estrogen receptors [ERα, ERβ, and G-protein associated ER (GPER)] in melanoma and skin may suggest their differential roles in carcinogenesis. Phytoestrogenic compound cyanidin-3-o-glucoside (C3G) has been shown to inhibit the growth and metastatic potential of melanoma, although the underlying molecular mechanism remains unclear. The aim of this study was to clarify the mechanism of action of C3G in melanoma in vitro and in vivo, as well as to characterize the functional expressions of ERs in melanoma. In normal skin or melanoma (n = 20/each), no ERα protein was detectable, whereas expression of ERβ was high in skin but weak focal or negative in melanoma; and finally high expression of GPER in all skin vs. 50% melanoma tissues (10/20) was found. These results correspond with our analysis of the melanoma survival rates (SRs) from Human Protein Atlas and The Cancer Genome Atlas GDC (362 patients), where low ERβ expression in melanoma correlate with a poor relapse-free survival, and no correlations were observed between SRs and ERα or GPER expression in melanoma. Furthermore, we demonstrated that C3G treatment arrested the cell cycle at the G2/M phase by targeting cyclin B1 (CCNB1) and promoted apoptosis via ERβ in both mouse and human melanoma cell lines, and inhibited melanoma cell growth in vivo. Our study suggested that C3G elicits an agonistic effect toward ERβ signaling enhancement, which may serve as a potential novel therapeutic and preventive approach for melanoma.